State Key Laboratory of Drug Research is affiliated to Shanghai Institute of Materia Medica, Chinese Academy of Sciences. The laboratory completed its construction and got accreditation from Chinese government in 1995. Professor Jian Ding is the current director of the laboratory and Professor Kai-Xian Chen is the chairman of the academic committee of the laboratory.
The research priorities of the laboratory are the drugs to treat major diseases, such as cancers, neurodegenerative diseases, metabolic diseases and infectious diseases. Both the natural products and synthetic drugs are investigated by using the state-of-the-art theories and technologies in chemistry and biology. Chemical, pharmacological and toxicological studies are collaborated to discover the bioactive substances and to develop new drugs. Novel mechanisms underlying drug action are explored on molecular, cellular and whole animal levels. Novel theories and innovative technologies for drug discovery are investigated.
There are 40 research personnel in the laboratory, including 3 members of Chinese Academy of Sciences and Chinese Academy of Engineering, 8 Outstanding Youth, 11 talents ofCAS Hundred Talents Project and 4 chief scientists of 973 Program. The recent achievements include Depsides Salt, a modernized TCM, for the treatment of coronary artery disease and Antofloxacin Hydrochloride, an anti-bacterial drug. Several compounds, such as Schiprine (anti-Alzheimer disease), Salvicine (anti-cancer) and Sulcardine Sulfate (anti-arrhythmia) are under clinical trials. Another 13 drug candidates are in preclinical studies.
In the national evaluation held in 2001 and 2006, the laboratory was listed in the top 6 and top 5 among nearly 60 key labs in the field of life sciences. Due to its research achievements and outstanding management, the laboratory was awarded in 2004 with a golden bull medal and certificate by Ministry of Science and Technology.